Hepatocellular carcinoma: a global view (original) (raw)
Ferlay, J. et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 Lyon, France: International Agency for Research on Cancer [online], (2010).
The World Health Organization GLOBOCAN 2002[online], (2002).
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S. & Fraumeni, J. F. Jr. International trends and patterns of primary liver cancer. Int. J. Cancer94, 290–296 (2001). CASPubMed Google Scholar
Altekruse, S. F., McGlynn, K. A. & Reichman, M. E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J. Clin. Oncol.27, 1485–1491 (2009). ArticlePubMedPubMed Central Google Scholar
Armstrong, G. L., Alter, M. J., McQuillan, G. M. & Margolis, H. S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology31, 777–782 (2000). CASPubMed Google Scholar
Davila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A. & El-Serag, H. B. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology127, 1372–1380 (2004). PubMed Google Scholar
Marrero, J. A. et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology36, 1349–1354 (2002). PubMed Google Scholar
Evans, A. A. et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol. Biomarkers Prev.7, 559–565 (1998). CASPubMed Google Scholar
El-Serag, H. B. & Rudolph, K. L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology132, 2557–2576 (2007). CASPubMed Google Scholar
Parkin, D. M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin.55, 74–108 (2005). PubMed Google Scholar
Naugler, W. E. et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science317, 121–124 (2007). CASPubMed Google Scholar
Yu, M. W. & Chen, C. J. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res.53, 790–794 (1993). CASPubMed Google Scholar
Bosch, F. X., Ribes, J., Diaz, M. & Cléries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology127 (Suppl. 1), S5–S16 (2004). PubMed Google Scholar
Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer118, 3030–3044 (2006). CASPubMed Google Scholar
Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer61, 1942–1956 (1988). CASPubMed Google Scholar
Chen, J. D. et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology138, 1747–1754 (2010). PubMed Google Scholar
Yuen, M. F. et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol.50, 80–88 (2009). PubMed Google Scholar
Yang, H. I. et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol.28, 2437–2444 (2010). PubMed Google Scholar
Liu, S. et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl Cancer Inst.101, 1066–1082 (2009). CASPubMedPubMed Central Google Scholar
Yang, H. I. et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl Cancer Inst.100, 1134–1143 (2008). CASPubMedPubMed Central Google Scholar
Kao, J. H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol. Int.1, 415–430 (2007). PubMedPubMed Central Google Scholar
Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295, 65–73 (2006). CASPubMed Google Scholar
Yang, H. I. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med.347, 168–174 (2002). CASPubMed Google Scholar
Frodsham, A. J. et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc. Natl Acad. Sci. USA103, 9148–9153 (2006). CASPubMedPubMed Central Google Scholar
Chu, C. J., Hussain, M. & Lok, A. S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology122, 1756–1762 (2002). CASPubMed Google Scholar
Chu, C. J. et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology125, 444–451 (2003). PubMed Google Scholar
Livingston, S. E. et al. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology133, 1452–1457 (2007). CASPubMed Google Scholar
Di Bisceglie, A. M. et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am. J. Gastroenterol.98, 2060–2063 (2003). PubMed Google Scholar
Sun, C. A. et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am. J. Epidemiol.157, 674–682 (2003). PubMed Google Scholar
Lam, J. P. et al. Infrequent vertical transmission of hepatitis C virus. J. Infect. Dis.167, 572–576 (1993). CASPubMed Google Scholar
Ohto, H. et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N. Engl. J. Med.330, 744–750 (1994). CASPubMed Google Scholar
Alter, M. J. et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med.341, 556–562 (1999). CASPubMed Google Scholar
Bronowicki, J. P. et al. Patient-to-patient transmission of hepatitis C virus during colonoscopy. N. Engl. J. Med.337, 237–240 (1997). CASPubMed Google Scholar
Mele, A. et al. Risk of parenterally transmitted hepatitis following exposure to surgery or other invasive procedures: results from the hepatitis surveillance system in Italy. J. Hepatol.35, 284–289 (2001). CASPubMed Google Scholar
Karmochkine, M., Carrat, F., Dos Santos, O., Cacoub, P. & Raguin, G. A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. J. Viral Hepat.13, 775–782 (2006). CASPubMed Google Scholar
Martínez-Bauer, E. et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J. Hepatol.48, 20–27 (2008). PubMed Google Scholar
Donahue, J. G. et al. The declining risk of post-transfusion hepatitis C virus infection. N. Engl. J. Med.327, 369–373 (1992). CASPubMed Google Scholar
Schreiber, G. B., Busch, M. P., Kleinman, S. H. & Korelitz, J. J. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N. Engl. J. Med.334, 1685–1690 (1996). CASPubMed Google Scholar
Hassan, M. M. et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology36, 1206–1213 (2002). CASPubMed Google Scholar
Ikeda, K. et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann. Intern. Med.146, 649–656 (2007). PubMed Google Scholar
Ohki, T. et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin. Gastroenterol. Hepatol.6, 459–464 (2008). PubMed Google Scholar
Lok, A. S. et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology136, 138–148 (2009). CASPubMed Google Scholar
Chen, C. L. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology135, 111–121 (2008). CASPubMed Google Scholar
El-Serag, H. B. & Mason, A. C. Risk factors for the rising rates of primary liver cancer in the United States. Arch. Intern. Med.160, 3227–3230 (2000). CASPubMed Google Scholar
Frezza, M. et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med.322, 95–99 (1990). CASPubMed Google Scholar
Donato, F. et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol.155, 323–331 (2002). CASPubMed Google Scholar
Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology129, 113–121 (2005). PubMed Google Scholar
Flegal, K. M., Carroll, M. D., Ogden, C. L. & Curtin, L. R. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303, 235–241 (2010). CASPubMed Google Scholar
Ogden, C. L. et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA295, 1549–1555 (2006). CASPubMed Google Scholar
Qian, G. S. et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev.3, 3–10 (1994). CASPubMed Google Scholar
Yu, S. Z. Primary prevention of hepatocellular carcinoma. J. Gastroenterol. Hepatol.10, 674–682 (1995). CASPubMed Google Scholar
Turner, P. C. et al. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J. Gastroenterol. Hepatol.17 (Suppl.), S441–S448 (2002). PubMed Google Scholar
Ni, Y. H. et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann. Intern. Med.135, 796–800 (2001). CASPubMed Google Scholar
Chang, M. H. et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst.101, 1348–1355 (2009). CASPubMed Google Scholar
Liaw, Y. F. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med.351, 1521–1531 (2004). CASPubMed Google Scholar
Matsumoto, A. et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol. Res.32, 173–184 (2005). CASPubMed Google Scholar
Yuen, M. F. et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther.12, 1295–1303 (2007). CASPubMed Google Scholar
Cammà, C., Giunta, M., Andreone, P. & Craxì, A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J. Hepatol.34, 593–602 (2001). PubMed Google Scholar
Nishiguchi, S. et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet357, 196–197 (2001). CASPubMed Google Scholar
Yoshida, H. et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med.131, 174–181 (1999). CASPubMed Google Scholar
Papatheodoridis, G. V., Papadimitropoulos, V. C. & Hadziyannis, S. J. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment. Pharmacol. Ther.15, 689–698 (2001). CASPubMed Google Scholar
Zhang, B. H., Yang, B. H. & Tang, Z. Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol.130, 417–422 (2004). PubMed Google Scholar
Trevisani, F. et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am. J. Gastroenterol.97, 734–744 (2002). PubMed Google Scholar
Marrero, J. A. et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology137, 110–118 (2009). CASPubMed Google Scholar
Bruix, J. & Sherman, M. Management of hepatocellular carcinoma. Hepatology42, 1208–1236 (2005). PubMed Google Scholar
Silva, M. A. et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut57, 1592–1596 (2008). CASPubMed Google Scholar
Llovet, J. M., Brú, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis.19, 329–338 (1999). CASPubMed Google Scholar
[No authors listed] A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology28, 751–755 (1998).
Lei, H. J. et al. Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J. Am. Coll. Surg.203, 426–435 (2006). PubMed Google Scholar
Okuda, K. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer56, 918–928 (1985). CASPubMed Google Scholar
Kudo, M., Chung, H. & Osaki, Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol.38, 207–215 (2003). PubMed Google Scholar
Forner, A., Reig, M. E., de Lope, C. R. & Bruix, J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin. Liver Dis.30, 61–74 (2010). CASPubMed Google Scholar
Farinati, F. et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer9, 33 (2009). PubMedPubMed Central Google Scholar
Imamura, H. et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol.38, 200–207 (2003). PubMed Google Scholar
Llovet, J. M., Fuster, J. & Bruix, J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology30, 1434–1440 (1999). CASPubMed Google Scholar
Teh, S. H. et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J. Gastrointest. Surg.9, 1207–1215 (2005). PubMed Google Scholar
Mazzaferro, V. et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med.334, 693–699 (1996). CASPubMed Google Scholar
Yao, F. Y. et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology33, 1394–1403 (2001). CASPubMed Google Scholar
D'Amico, F. et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl.15, 1278–1287 (2009). PubMed Google Scholar
Yao, F. Y. et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl.11, 1505–1514 (2005). PubMed Google Scholar
Yao, F. Y. et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology48, 819–827 (2008). PubMed Google Scholar
Trotter, J. F., Wachs, M., Everson, G. T. & Kam, I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N. Engl. J. Med.346, 1074–1082 (2002). PubMed Google Scholar
Vakili, K. et al. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival. Liver Transpl.15, 1861–1866 (2009). PubMed Google Scholar
Vilana, R. et al. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology16, 353–357 (1992). CASPubMed Google Scholar
Lin, S. M., Lin, C. J., Lin, C. C., Hsu, C. W. & Chen, Y. C. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology127, 1714–1723 (2004). PubMed Google Scholar
Chen, M. S. et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann. Surg.243, 321–328 (2006). PubMedPubMed Central Google Scholar
Lau, W. Y. & Lai, E. C. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann. Surg.249, 20–25 (2009). PubMed Google Scholar
Livraghi, T. et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology47, 82–89 (2008). PubMed Google Scholar
Lü, M. D. et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial [Chinese]. Zhonghua Yi Xue Za Zhi86, 801–805 (2006). PubMed Google Scholar
Llovet, J. M. et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet359, 1734–1739 (2002). PubMed Google Scholar
Lo, C. M. et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology35, 1164–1171 (2002). CASPubMed Google Scholar
Alba, E. et al. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation. AJR Am. J. Roentgenol.190, 1341–1348 (2008). PubMed Google Scholar
Chan, A. O., Yuen, M. F., Hui, C. K., Tso, W. K. & Lai, C. L. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer94, 1747–1752 (2002). PubMed Google Scholar
Dhanasekaran, R. et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J. Surg. Oncol.101, 476–480 (2010). PubMed Google Scholar
Lammer, J. et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc. Intervent. Radiol.33, 41–52 (2010). PubMed Google Scholar
Geschwind, J. F. et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology127 (Suppl. 1), S194–S205 (2004). CASPubMed Google Scholar
Sangro, B. et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys.66, 792–800 (2006). CASPubMed Google Scholar
Roberts, L. R. & Gores, G. J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis.25, 212–225 (2005). CASPubMed Google Scholar
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med.359, 378–390 (2008). CASPubMed Google Scholar
Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol.10, 25–34 (2009). CASPubMed Google Scholar
ClinicalTrials.gov Sorafenib as adjuvant treatment in the prevention of recurrence of hepatocellular carcinoma (STORM)[online], (2010).
ClinicalTrials.gov A phase II randomized, double-blind, placebo-controlled study of sorafenib or placebo in combination with transarterial chemoembolization (TACE) performed with DC bead and doxorubicin for intermediate stage hepatocellular carcinoma (HCC)[online], (2010).
The World Gastrointestinal Organization WGO practice guideline—hepatocellular carcinoma (HCC): a global perspective[online], (2009).
Bruix, J. et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol.35, 421–430 (2001). CASPubMed Google Scholar
Bendavid, E. & Bhattacharya, J. The President's Emergency Plan for AIDS Relief in Africa: an evaluation of outcomes. Ann. Intern. Med.150, 688–695 (2009). PubMedPubMed Central Google Scholar
US Centers for Disease Control and Prevention Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[online], (2008).
WHO International Travel and Health Global prevalence of hepatitis A, B and C[online], (2002).